110 related articles for article (PubMed ID: 2504680)
21. Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells.
Walewski J; Paietta E; Dutcher J; Wiernik PH
J Cancer Res Clin Oncol; 1989; 115(2):170-4. PubMed ID: 2654134
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
Espevik T; Figari IS; Ranges GE; Palladino MA
J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
[TBL] [Abstract][Full Text] [Related]
23. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
25. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
27. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
28. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
29. Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer.
Matsunaga H; Kuwahara Y; Kusugami K; Morise K; Shimokata K
Gastroenterol Jpn; 1988 Oct; 23(5):527-33. PubMed ID: 3145895
[TBL] [Abstract][Full Text] [Related]
30. Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients.
Logan TF; Gooding WE; Whiteside TL; Ernstoff MS; Kaplan SS; Miketic L; Vlock DR; Tompkins C; Wood DL; Nadler PI; Kirkwood JM
J Immunother; 1997 Sep; 20(5):387-98. PubMed ID: 9336746
[TBL] [Abstract][Full Text] [Related]
31. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
Di Raimondo F; LaPushin R; Hersh EM
Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
[TBL] [Abstract][Full Text] [Related]
32. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin.
Sredni B; Kalechman Y; Albeck M; Gross O; Aurbach D; Sharon P; Sehgal SN; Gurwith MJ; Michlin H
Immunology; 1990 Aug; 70(4):473-7. PubMed ID: 2118479
[TBL] [Abstract][Full Text] [Related]
33. [Augmentation of natural killer (NK) cell activity in human blood lymphocytes by a new synthetic acyltripeptide (FK-565) and its derivatives].
Shimizu E; Tandon P; Utsugi T; Sone S
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2353-7. PubMed ID: 3460529
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of cytokine production and natural killer activity by an Escherichia coli extract.
Wybran J; Libin M; Schandene L
Onkologie; 1989 Jun; 12 Suppl 3():22-5. PubMed ID: 2514401
[TBL] [Abstract][Full Text] [Related]
35. IL-2-activated cord blood mononuclear cells.
Derzic S; Slone V; Sender L
Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
[TBL] [Abstract][Full Text] [Related]
36. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
37. Activation of natural killer cells and cytokine production in man by bacterial extracts.
Wybran J; Libin M; Schandene L
Immunopharmacol Immunotoxicol; 1989; 11(1):17-32. PubMed ID: 2503554
[TBL] [Abstract][Full Text] [Related]
38. Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients.
Karimine N; Arinaga S; Inoue H; Nanbara S; Ueo H; Akiyoshi T
Clin Exp Immunol; 1994 Jun; 96(3):484-90. PubMed ID: 8004819
[TBL] [Abstract][Full Text] [Related]
39. Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.
Yoneda K; Osaki T; Yamamoto T; Ueta E
Clin Exp Immunol; 1993 Aug; 93(2):229-36. PubMed ID: 8348749
[TBL] [Abstract][Full Text] [Related]
40. Cytolysis of human dendritic cells by autologous lymphokine-activated killer cells: participation of both T cells and NK cells in the killing.
Parajuli P; Nishioka Y; Nishimura N; Singh SM; Hanibuchi M; Nokihara H; Yanagawa H; Sone S
J Leukoc Biol; 1999 Jun; 65(6):764-70. PubMed ID: 10380897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
